Experience Meets Innovation: How Corval Leverages Decades of Biopharma Expertise Using AI

by Casey Ryan with Paul Sohal

Where Experience Meets Innovation

In a May 2023 post, The Boston Consulting Group emphasized, “Companies that both prioritize innovation and make sure that they are ready to act are widening the gap over less capable competitors.” Corval epitomizes this philosophy. We aren’t just embracing innovation; we are pioneering it.

While Corval is a technology-based solution, the heart of the platform is human mastery and governance. Users can experience the benefits of AI technology while being assured their commercialization plan is produced with the accuracy and reliability of real-life biopharma expertise.

Corval combines the accuracy and depth of a commercialization plan built by biopharma industry experts with the speed and adaptability of AI software. We understand the concerns regarding AI-generated information—intellectual property, data integrity, regulatory compliance, and patient privacy—to name a few. In the realm of biopharma, the stakes are high due to the level of investment, time for development, and patient need for the novel therapy. Corval was built to ease the commercialization process of bringing assets to the market. Corval utilizes an AI system that leverages validated data and logic that is meticulously and regularly reviewed by biopharma experts. This is not generative AI but human knowledge refined and perfected over decades to provide you with the commercialization information you need when you need it in a technology solution that represents the rigor that is integral to our complex industry.

Within the realm of developing generative AI for commercialization planning, leaders encounter a persistent challenge—the scarcity of fine-grained, publicly accessible data. The sheer magnitude of data required to train a sophisticated, generative AI engine for delivering precise and unwavering results remains an elusive goal. However, at Corval, we recognized we could capture the wealth and breadth of the biopharma commercialization wisdom from our seasoned leaders, our vast network, and twenty years of consulting projects. We are harnessing that resource to create a rule-based AI engine, bridging the gap between commercialization planning and AI technology.

Within Corval is a unique combination of decades of real-world human expertise leveraged by cutting-edge AI technology, which is the epitome of experience capitalizing on innovation to serve an important need.

The Heart of Corval

At the heart of Corval is an innovative algorithm that is optimized for shaping commercialization roadmaps, budgets, and hiring plans. This complex AI rules engine is underpinned by a vast repository of over 75,000 data points derived from decades of biopharma experience. This amalgamation of data and expertise sets Corval apart in the industry to transform an otherwise time-consuming fragmented process of building a multi-faceted plan spanning early commercialization to launch—a 2- to 5-year horizon.

Drawing from its tremendous data repository, the Corval AI rules engine applies its proprietary logic to assemble personalized commercialization plans with unparalleled clarity. User-provided inputs allow Corval to generate a plan that will fit your company’s strategy and timeline.

In today’s dynamic biopharma landscape, adaptability is crucial. The Corval AI rules engine enables robust adjustments based on new insights received throughout the development and commercialization horizon, allowing users to adjust to change in stride. When your commercialization needs and timeline change, Corval is flexible and can adapt to produce a new plan to get your asset to market successfully while you communicate to stakeholders with ease along the way.

Looking to the Future

 While our platform already showcases AI-driven decision-making capabilities, we're excited about the future. The prospect of machine learning opens endless possibilities for even more refined outcomes and more personalized user experiences. The future is bright with and for AI in biopharma commercialization. We are thrilled to be leading the way, applying our collective wisdom in ways never done before.

The Corval AI-powered approach represents a new era in biopharma commercialization strategy. Our tailored plans, reliability, and credibility exemplify our commitment to creating a clear path to market, enabling biopharma leaders to focus on delivering life-changing treatments to patients. Corval brings technology and human ingenuity together, unlocking the full potential of biopharma innovation.

Experience truly meets innovation at Corval.

To speak to one of our commercialization experts about your asset's unique journey to market, reach out to us here.